ArticleFrontiers in genetics2021
Genomic Analysis of Multidrug-Resistant
Article in Frontiers in genetics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 12 citations in OpenAlex.
- Article
- Treatment outcomes for drug-resistant tuberculosis: a retrospective longitudinal study.BMC infectious diseases · 2025Article
- Multidrug-Resistant Tuberculosis in Central Asia and Predominant Beijing Lineage, Challenges in Diagnosis, Treatment Barriers, and Infection Control Strategies: An Integrative Review.Antibiotics (Basel, Switzerland) · 2025Review
- Trends and disparities in tuberculosis burden in Kazakhstan and Mongolia (2017-2021): a comparative analysis using GBD metrics.Frontiers in public health · 2025Article
- Genetic diversity, drug resistance, and transmission patterns of tuberculosis based on whole-genome sequencing in Almaty, Kazakhstan.Frontiers in microbiology · 2025Article
- Antimicrobial Resistance Surveillance in Post-Soviet Countries: A Systematic Review.Antibiotics (Basel, Switzerland) · 2024Review
- Clinical course of respiratory tuberculosis relapses in the Kazakh population depending on HLA-DRB1 gene alleles.Virusdisease · 2024Article
- Genetic diversity, evolution and drug resistance ofFrontiers in microbiology · 2024Review
- Prevalence of Beijing Central Asian/Russian Cluster 94-32 among Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Draft genome sequence of a multidrug-resistantMicrobiology resource announcements · 2023Article
- Epidemiology of tuberculosis in Kazakhstan: data from the Unified National Electronic Healthcare System 2014-2019.BMJ open · 2023Article
- Genomic Characterization of Drug-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Whole-Genome Sequence-Based Characterization of Pre-XDRDiagnostics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberculosis (TB) is an infectious disease that remains an essential public health problem in many countries. Despite decreasing numbers of new cases worldwide, the incidence of antibiotic-resistant forms (multidrug resistant and extensively drug-resistant) of TB is increasing. Next-generation sequencing technologies provide a high-throughput approach to identify known and novel potential genetic variants that are associated with drug resistance in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.